tbuckley/cabot-search huggingface dataset:
Effect of tandem high-dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: Mature results of the IBDIS-I
Authors: J. P. Crown, S. Leyvraz, M. Verrill, V. Guillem, A. Efremidis, J. Garcia-Conde Bru, R. Welch, A. Montes, R. Leonard, J. Baselga
Journal: Journal of Clinical Oncology (2004)

631 Background: In single arm studies, HDC (usually single-cycle) with autograft support appeared to produce an unusually high percentage of LTCR in MBC, an observation which was not confirmed in prospective randomised trials (PRT). We have previously reported the results of the protocol-mandated interim three-year analysis of IBDIS I-a, prematurely terminated (post-Bezwoda)PRT of HDC versus CDC in MBC (ASCO 2003). Despite relatively small numbers (110pts), the primary protocol endpoint-event-free survival (EFS i.e. alive without relapse)-was statistically significantly superior for HDC pts. We now present updated results. Methods: PRT in pts without prior CDC for MBC. CDC (mg/m2): doxorubicin 50/ docetaxel 75 (AT) x 4 followed by cyclophosphamide / methotrexate/5FU; versus HD: 3xAT followed by tandem autograft-supported HDC (#1-Ifosphamide12,000/carboplatin AUC18/etoposide 1200; #2:-cyclophosphamide 6000/thiotepa 800). The median five year F/U will coincide with ASCO 2004, however, as median EFS will still be statistically significantly superior in 5/2004 even if all remaining HDC CR relapse immediately, it was decided to analyze the data now, at 55 months of F/U. Results: All are intention to treat. The study remains statistically significantly positive at a median follow-up of 55 months (range 76–30) The median EFS were: HDC 416 and CDC 312 days (EFS: p=0.017 log-rank, RR 0.62). Progression–free survivals were: HDC 439, CDC 322 days (RR=0.57; p=.006). There were 5 treatment-related deaths on HDC, and 2 on CDC. Six of 56 HDC pts are still alive and relapse free (74, 62, 56, 56, 55, 54 months), versus 1 CDC patient (49 months). Nineteen HDC pts are alive, versus 10 CDC (median survival: 961v 804 days, RR=0.68; p=0.08) Conclusion: These results do not justify routine HDC, but, given the failure of other treatments to produce a meaningful rate of LTCR in this "incurable cancer", do mandate further study of this approach. IBDIS II will soon be open for accrual. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis
"THE STRUCTURE OF MUSCLES"
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CD8αα+ Innate-Type Lymphocytes in the Intestinal Epithelium Mediate Mucosal Immunity
Authors: Luc Van Kaer, Holly M. Scott Algood, Kshipra Singh, Vrajesh V. Parekh, Michael J. Greer, M. Blanca Piazuelo, Jörn-Hendrik Weitkamp, Pranathi Matta, Rupesh Chaturvedi, Keith T. Wilson, Danyvid Olivares-Villagómez
Journal: Immunity (2014)
PATH-18. SUBCLASSIFICATION OF LOW-GRADE GLIOMAS CONSIDERING TERT PROMOTER MUTATION AND ATRX LOSS: BEYOND THE 2016 WHO CLASSIFICATION
Authors: Jong Hee Chang, Tae Hoon Roh, Ju Hyung Moon, Eui Hyun Kim, Seok-Gu Kang, Se Hoon Kim, Chang-Ok Suh
Journal: Neuro-Oncology (2018)

Grade II glioma is a heterogeneous group of various pathologies. 2016 WHO classification defined subgroups of Grade II gliomas based on isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion status. However, implications of telomerase reverse transcriptase promoter (TERTp) mutation and alpha-thalassemia/mental retardation syndrome X-linked (ATRX) loss are not considered in the classification. Patients (n = 191) who underwent surgery and pathologically proven for supratentorial newly diagnosed low-grade glioma (WHO grade II) were included this study. Molecular diagnoses including IDH1/2 mutation, 1p/19q codeletion, TERTp mutation, ATRX expression, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status was evaluated. The overall survival according to TERTp mutation and ATRX loss in each 2016 WHO class were compared. There were 34 (17.8%) IDH-wildtype astrocytomas, 81 (42.4%) IDH-mutant astrocytomas, and 76 (39.8%) IDH-mutant and 1p/19q-codeleted oligodendrogliomas. The median overall survival (OS) of each group were 3.9, 10.4, and 18.7 years, respectively. TERTp mutation had negative impact for survival in IDH-wildtype astrocytomas (HR = 5.458, 95% confidence interval [CI] 1.771–16.826), while no significant differences were observed regarding TERTp mutation in IDH-mutant astrocytomas and oligodendrogliomas. Among IDH-wildtype/TERTp-mutant astrocytomas, ATRX loss was significantly correlated with poor outcome (2.1 vs 3.0 years, p=0.033). CONCLUSIONS: Molecular status of TERTp mutation and ATRX expression can help stratifying IDH-wildtype astrocytomas. IDH-wildtype astrocytomas which harbor TERTp mutation only without ATRX loss showed the worst outcome. Further study is needed to verify the role of TERTp mutation and ATRX in gliomas.
SANITATION AND SUBSISTENCE AT PANAMA.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manuscripts Approved for JNCI, March-April, 1973
Journal: JNCI Journal of the National Cancer Institute (1973)

Manuscripts Approved for JNCI, March-April, 1973 Get access JNCI: Journal of the National Cancer Institute, Volume 50, Issue 5, May 1973, Pages 1416–1418, https://doi.org/10.1093/jnci/50.5.1416-a Published: 01 May 1973
MORE ROACH POISON
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Periodic breast cancer screening in reducing mortality from breast cancer
Authors: S. Shapiro
Journal: JAMA (1971)

First results in a long-term investigation to determine whether periodic breast cancer screening with mammography and clinical examination leads to lowered breast cancer mortality provide grounds for cautious optimism. The study compares the experience in a random sample of 31,000 women, aged 40 to 64 years, offered screening examinations with the experience in a similarly constituted "control" group. There were 52 deaths due to breast cancer in the control group, as compared with 31 breast cancer deaths in the study group, in the period available for follow-up. The 3 1/2-year case fatality rates among women with histologically confirmed breast cancers reinforce the impression that screening leads to lowered mortality. More time, possibly ten years of follow-up, is needed to establish whether the effect of the screening program is short-term or long-term.
lpr And gld: Single Gene Models Of Systemic Autoimmunity And Lymphoproliferative Disease
Authors: P. Cohen
Journal: Annual Review of Immunology (1991)

The autosomal recessive lpr and gld genes induce in mice multiple autoantibodies and the progressive accumulation of large numbers of non-malignant CD4- CD8- T lymphocytes. The clinical syndromes and immune abnormalities associated with these two nonallelic genes are nearly identical and are also highly dependent on background genes. MRL/lpr mice are particularly severely affected, and they develop a syndrome that is serologically and pathologically similar to human systemic lupus erythematosus (SLE). Abnormal cell marker expression in the aberrant lpr T lymphocytes includes surface antigens normally associated with activated T cells or even with B cells, and it occurs along with enhanced expression of certain oncogenes. The lpr gene results in intrinsic abnormalities of both T and B lymphocytes, yet its location and product are unknown. The gld gene is located on chromosome 1; its product is also unknown. Although many immunological abnormalities are known, the mechanism whereby these two genes induce autoimmunity and lymphoproliferation remains obscure. Further studies of mice bearing these mutant genes are certain to yield insights into systemic autoimmunity and the control of lymphocyte proliferation.
Increased Second Trimester Maternal Glucose Levels Are Related to Extremely Large-for-Gestational-Age Infants in Women With Type 1 Diabetes
Authors: Anneloes Kerssen, Harold W. de Valk, Gerard H.A. Visser
Journal: Diabetes Care (2007)

OBJECTIVE—Large-for-gestational-age (LGA) infants (birth weight ≥90th centile) are a continuing problem in pregnancies of women with type 1 diabetes. We used the continuous glucose monitoring system (CGMS) to assess the relationship between 24-h diurnal glucose profiles in all three trimesters of pregnancy and infant birth weight. RESEARCH DESIGN AND METHODS—Twenty-nine pregnant women with type 1 diabetes used the CGMS during each trimester of pregnancy. The glucose profiles of the women with a normal-weight infant or an LGA infant were compared. RESULTS—Of the women with type 1 diabetes, 48% gave birth to an LGA infant. Fifty percent of these infants were already large for dates on ultrasound at &amp;lt;30 weeks of gestation (early LGA), and all these infants had a birth weight ≥97.7th centile. The diurnal glucose profiles show that the mothers of early LGA infants had elevated glucose levels for most of the day during the second trimester (P &amp;lt; 0.05). The median 24-h glucose level was significantly higher in women who gave birth to early LGA infants in all three trimesters of pregnancy (6.7, 8.3, and 6.5 mmol/l for the first, second, and third trimesters, respectively). Within the group of women with early LGA infants, the second trimester median glucose level was significantly higher than that in the first and third trimester (P &amp;lt; 0.05). CONCLUSIONS—In women with type 1 diabetes, extreme growth of the fetus starts early in pregnancy and is likely caused by increased maternal glucose levels. Further investigation is needed to see whether early tight glycemic control will reduce the number of extreme LGA infants.
Blunted natriuretic response to low-dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention*1
Authors: G LAVILLA
Journal: Hepatology (1995)

Patients with cirrhosis and ascites have high plasma levels of atrial (ANP) and brain (BNP) natriuretic peptides, two cardiac hormones released by the atria and ventricles, respectively. We evaluated renal hemodynamics, sodium excretion, and intrarenal sodium handling (lithium clearance method) in seven cirrhotic patients with ascites and avid sodium retention before, during, and after the infusion of synthetic human BNP, at the dose of 4 pmol/kg · min for 1 hour, which has been shown to increase renal plasma flow, glomerular filtration rate (GFR), and sodium excretion in healthy subjects without affecting systemic hemodynamics. Plasma BNP levels were 7.31 ± 0.85 pmol/L in baseline conditions, and increased to 33.60 ± 2.96 pmol/L at the end of the infusion (P < .01 vs. baseline). Urinary excretion of guanosine 3′,5′-cyclic monophosphate (cGMP) also significantly increased during the infusion, indicating stimulation of natriuretic peptide receptors by BNP. BNP administration did not modify renal plasma flow, GFR, sodium excretion or tubular sodium reabsorption to any appreciable extent. Arterial pressure heart rate, plasma norepinephrine, and plasma renin activity (PRA) where also unchanged, whereas plasma aldosterone concentration showed a significant, 35% reduction at the end of the postinfusion period, ruling out the possibility that BNP-induced vasodilation might be responsible for failure of the peptide to induce a natriuretic response. Overactivity of antinatriuretic factors is probably the main determinant of the blunted natriuretic effect of BNP in these patients.
Reading Plans
Authors: John G. Morrison
Journal: JAMA (1983)

<h3>To the Editor.—</h3> I read the COMMENTARY entitled "A Realistic Journal Reading Plan" by Dr William E. Scheckler (1982;248:1987). No one can disagree with Dr Scheckler that "sensible" reading plans can be the cornerstone of professional growth. However, his comments concerning the use of audiotapes in the learning process deserve some rebuttal. Although Dr Scheckler is "not a fan of audiotapes in general," he apparently assumes that this mode is always used while driving an automobile. This is certainly not the exclusive use of taped material, as evidenced by the number of physicians who complete the pretesting and posttesting materials that accompany each audio program. This can hardly be done while driving. The advantages of audiotape in the milieu of continuing medical education (CME) are many, not the least of which is access to educational material long before the printed word. The accompanying printed material with each cassette lends itself
Circulation, Pharmacology, and Shock
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Community Medicine
Authors: JOSEPH STOKES
Journal: Annals of Internal Medicine (1972)

Letters, Comments, and Corrections1 September 1972Community MedicineJOSEPH STOKES III, M. D.JOSEPH STOKES III, M. D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-77-3-475 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: I read with care the lead article in the May 1972 issue of theAnnals of Internal Medicine(76:689-695), "Community Medicine: An Evolving Discipline," in which Challenor, Wicks, and Lythcott grappled with issues with which our own department has come to grips. . . . Although I agree. . .that there is an urgent need for crisp definition of these matters, I do not share their overly expansive concept of our discipline. I counted at least eight definitions of community medicine in the first seven paragraphs, all of which they imply can be encompassed at Columbia by... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JOSEPH STOKESIII, M. D.Affiliations: Department of Community Medicine School of Medicine University of California, San Diego La Jolla, Calif. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1972Volume 77, Issue 3Page: 475-476KeywordsHand strength ePublished: 1 December 2008 Issue Published: 1 September 1972 PDF downloadLoading ...
Statistical Computing in the United States
Authors: Roy C. Milton
Journal: Environmental Health Perspectives (1979)

Recent history and developments related to the increase in statistical computing activities in the United States and by U.S. participants in international efforts are reviewed, with emphasis on important events, organizations, references, and products which contribute to informed selection and use of statistical programs. Three features matrices for major statistical packages are included as potential aids to Japanese statisticians in assessing the utility of these packages in biostatistical applications.
Social Activities
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hazard of chemical sympathectomy.
Authors: A Rubin, B Master
Journal: BMJ (1978)

<h3>Introduction</h3> Emergency department (ED) visits for epilepsy are common, costly, often clinically unnecessary and typically lead to little benefit for epilepsy management. An ‘Alternative Care Pathway’ (ACP) for epilepsy, which diverts people with epilepsy (PWE) away from ED when ‘999’ is called and leads to care elsewhere, might generate savings and facilitate improved ambulatory care. It is unknown though what features it should incorporate to make it acceptable to persons from this particularly vulnerable target population. It also needs to be National Health Service (NHS) feasible. This project seeks to identify the optimal ACP configuration. <h3>Methods and analysis</h3> Mixed-methods project comprising three-linked stages. In Stage 1, NHS bodies will be surveyed on ACPs they are considering and semi-structured interviews with PWE and their carers will explore attributes of care important to them and their concerns and expectations regarding ACPs. In Stage 2, Discrete Choice Experiments (DCE) will be completed with PWE and carers to identify the relative importance placed on different care attributes under common seizure scenarios and the trade-offs people are willing to make. The uptake of different ACP configurations will be estimated. In Stage 3, two Knowledge Exchange workshops using a nominal group technique will be run. NHS managers, health professionals, commissioners and patient and carer representatives will discuss DCE results and form a consensus on which ACP configuration best meets users’ needs and is NHS feasible. <h3>Ethics and dissemination</h3> Ethical approval: NRES Committee (19/WM/0012) and King’s College London ethics Committee (LRS-18/19-10353). Primary output will be identification of optimal ACP configuration which should be prioritised for implementation and evaluation. A pro-active dissemination strategy will make those considering developing or supporting an epilepsy ACP aware of the project and opportunities to take part in it. It will also ensure they are informed of its findings. <h3>Project registration number</h3> Researchregistry4723.